Literature DB >> 26198584

Trends in Warfarin Monitoring Practices Among New York Medicare Beneficiaries, 2006-2011.

Darren M Triller1, Susan Wymer, Patrick D Meek, Elaine M Hylek, Jack E Ansell.   

Abstract

Anticoagulation with warfarin requires frequent evaluation of the international normalized ratio (INR), and less invasive testing devices are available for use by clinicians at the point-of-care (POC) and by patients who self-test (PST). Despite commercial availability and positive results of published studies, evidence suggests that adoption of less invasive (POC/PST) testing in the United States is slow. Considering the equivalence of results and logistical advantages of POC/PST testing, slow uptake may indicate a gap in quality of care warranting evaluation and possibly intervention. This study used Medicare fee for service claims data to explore the uptake of POC/PST INR monitoring across New York State over a 6 year time frame (2006-11), with additional analyses based on beneficiary age, sex, race and ethnicity and income by county. In 2006, only 28.3% of 103,410 analyzable beneficiaries presumed to be chronic warfarin users based on INR testing patterns were monitored by POC/PST, and increased to only 37.6% by 2011. Utilization of POC/PST testing varied widely by county (baseline range 1.2-89.4%), and uptake of these testing modalities in New York State was significantly lower among the very elderly, women, and ethnic minorities. We hypothesize that poor penetration of these less invasive INR testing modalities into highly populated New York City and barriers to POC utilization in long term care facilities may account for a portion of the variability in INR testing patterns observed in this study. However, additional research is needed to further explore whether disparities in warfarin monitoring practices exist.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26198584     DOI: 10.1007/s10900-015-0066-5

Source DB:  PubMed          Journal:  J Community Health        ISSN: 0094-5145


  22 in total

1.  Risk of bleeding with dabigatran in atrial fibrillation.

Authors:  Inmaculada Hernandez; Seo Hyon Baik; Antonio Piñera; Yuting Zhang
Journal:  JAMA Intern Med       Date:  2015-01       Impact factor: 21.873

2.  Warfarin management using point-of-care testing in a university-based internal medicine resident clinic.

Authors:  Marcus Smith; Donald Harrison; Toni Ripley; Sarah Grace; Michael S Bronze; Rhett Jackson
Journal:  Am J Med Sci       Date:  2012-10       Impact factor: 2.378

3.  Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.

Authors: 
Journal:  Am Heart J       Date:  2010-03       Impact factor: 4.749

4.  Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

Authors:  David J Graham; Marsha E Reichman; Michael Wernecke; Rongmei Zhang; Mary Ross Southworth; Mark Levenson; Ting-Chang Sheu; Katrina Mott; Margie R Goulding; Monika Houstoun; Thomas E MaCurdy; Chris Worrall; Jeffrey A Kelman
Journal:  Circulation       Date:  2014-10-30       Impact factor: 29.690

5.  A team-based approach to warfarin management in long term care: a feasibility study of the MEDeINR electronic decision support system.

Authors:  Alexandra Papaioannou; Courtney C Kennedy; Glenda Campbell; Jacqueline B Stroud; Luqi Wang; Lisa Dolovich; Mark A Crowther
Journal:  BMC Geriatr       Date:  2010-06-10       Impact factor: 3.921

6.  Improving warfarin safety in long-term care.

Authors:  Darren Triller; Susan Wymer; Karen Morris; Gayle Farman; Anne Myrka
Journal:  Consult Pharm       Date:  2014-07

7.  Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population.

Authors:  Beth Nochowitz; Nancy L Shapiro; Edith A Nutescu; Larisa H Cavallari
Journal:  Ann Pharmacother       Date:  2009-06-23       Impact factor: 3.154

8.  Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation.

Authors:  Benjamin A Steinberg; Dajuanicia N Holmes; Jonathan P Piccini; Jack Ansell; Paul Chang; Gregg C Fonarow; Bernard Gersh; Kenneth W Mahaffey; Peter R Kowey; Michael D Ezekowitz; Daniel E Singer; Laine Thomas; Eric D Peterson; Elaine M Hylek
Journal:  J Am Heart Assoc       Date:  2013-11-25       Impact factor: 5.501

9.  The clinical impact of different coagulometers on patient outcomes.

Authors:  Jan Leendert Pouwel Brouwer; Hugo Stoevelaar; Christoph Sucker
Journal:  Adv Ther       Date:  2014-06-04       Impact factor: 3.845

10.  Atrial fibrillation, stroke, and anticoagulation in Medicare beneficiaries: trends by age, sex, and race, 1992-2010.

Authors:  Gautam R Shroff; Craig A Solid; Charles A Herzog
Journal:  J Am Heart Assoc       Date:  2014-06-03       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.